Estrogenic Agonist Activity of ICI 182,780 (Faslodex) in Hippocampal Neurons: Implications for Basic Science Understanding of Estrogen Signaling and Development of Estrogen Modulators with a Dual Therapeutic Profile
Open Access
- 1 September 2006
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 319 (3), 1124-1132
- https://doi.org/10.1124/jpet.106.109504
Abstract
The present study sought to determine the characteristics of ICI 182,780 (Faslodex) action in rat primary hippocampal neurons. We first investigated the neuroprotective efficacy of ICI 182,780 against neurodegenerative insults associated with Alzheimer's disease and related disorders. Dose-response analyses revealed that ICI 182,780, in a concentration-dependent manner, significantly promoted neuron survival following exposure to either excitotoxic glutamate (200 μM)- or β-amyloid1–42 (1.5 μM)-induced neurodegeneration of hippocampal neurons. At a clinically relevant concentration of 50 ng/ml, ICI 182,780 exerted nearly maximal neuroprotection against both insults with efficacy comparable with that induced by the endogenous estrogen 17β-estradiol. Thereafter, we investigated the impact of 50 ng/ml ICI 182,780 on mechanisms of 17β-estradiol-inducible neuronal plasticity and neuroprotection. Results of these analyses demonstrated that ICI 182,780 directly induced a series of rapid intracellular Ca2+ concentration ([Ca2+]i) oscillations in a pattern comparable with that of 17β-estradiol. In addition, ICI 182,780 exerted dual regulation of the glutamate-induced rise in [Ca2+]i identical to that induced by 17β-estradiol. Further analyses demonstrated that ICI 182,780 induced significant activation of extracellular signal-regulated kinase 1/2 and Akt (protein kinase B) and significantly increased expression of spinophilin and Bcl-2, with efficacy comparable with neurons treated with 17β-estradiol. Taken together, results of these in vitro analyses of ICI 182,780 provide direct evidence of an estrogenic agonist profile of ICI 182,780 action in rat hippocampal neurons. Therapeutic development of neuroselective estrogen receptor modulators that mimic ICI 182,780 is discussed with respect to the potential of safe and efficacious alternatives to estrogen therapy for the prevention of postmenopausal cognitive decline and late-onset Alzheimer's disease.This publication has 38 references indexed in Scilit:
- Non-nuclear estrogen receptor ? and ? in the hippocampus of male and female ratsHippocampus, 2005
- Morphological Effects of Estrogen on Cholinergic NeuronsIn VitroInvolves Activation of Extracellular Signal-Regulated KinasesJournal of Neuroscience, 2004
- FDA Drug Approval Summaries: FulvestrantThe Oncologist, 2002
- Nongenomic mechanism mediates estradiol stimulation of axon growth in male rat hypothalamic neurons in vitroJournal of Neuroscience Research, 2001
- Cellular and Molecular Mechanisms of Estrogen Regulation of Memory Function and Neuroprotection Against Alzheimer's Disease: Recent Insights and Remaining ChallengesLearning & Memory, 2001
- ICI 182,780 (Faslodex?)Cancer, 2000
- Spinophilin regulates the formation and function of dendritic spinesProceedings of the National Academy of Sciences of the United States of America, 2000
- Molecular basis of agonism and antagonism in the oestrogen receptorNature, 1997
- Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancerBritish Journal of Cancer, 1996
- Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.Proceedings of the National Academy of Sciences of the United States of America, 1990